2016-03-12T00:00:00.000-05:00
Goldman Sachs,-0.546431
strong buy rating,0.372769
Columbus Circle Investors,0.369626
Alexion Pharmaceuticals stock,-0.214653
life-transforming therapeutic products,0.447843
Vanguard Group Inc.,0.273384
Asset Management Inc.,0.445672
Brown Advisory Inc.,0.225902
Calamos Advisors,0.469628
Alexion Pharmaceuticals Inc.,0.560435
InvestorPlace Broker Center,0.555736
TD Asset Management,0.445672
average price target,-0.3348
biopharmaceutical company,0.363149
research report,0.264795
Alexion Pharmaceuticals,0.118041
CFO Vikas Sinha,-0.212722
sell rating,0.380178
metabolic rare disease,-0.206178
personal trading style,0.598412
target price,-0.491949
average price,0.175548
shares,0.109016
executive vice president,0.214786
concise daily summary,0.448938
quarterly revenue,-0.403041
stock broker,0.245696
consensus rating,0.405552
complement inhibitor portfolio,0.306346
equities research analyst,0.380178
quarter,0.0324796
EVP Clare Carmichael,-0.216585
